EGFR and non-small cell lung carcinoma: Many randomized phase III trials showed, in patients with advanced NSCLC and common EGFR mutations, the superiority of EGFR TKIs, i.e. gefitinib, erlotinib, afatinib, in the first line of treatment compared to standard platinum-based chemotherapy, in terms of both RR and PFS (4).